Review anchor
Aldo-keto reductase family 1 member B1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Aldo-keto reductase family 1 member B1
CHEMBL1900
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Aldo-keto reductase family 1 member B1 as ChEMBL target CHEMBL1900, mapped to UniProt P15121. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1900
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15121
Aldo-keto reductase family 1 member B1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Aldo-keto reductase family 1 member B1 matters
Aldo-keto reductase family 1 member B1 is reviewed as Aldo-keto reductase family 1 member B1 (UniProt P15121); Aldo-keto reductase family 1 member B1 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 1035 compounds, and 224 assays, with lead potency reaching pChEMBL 9.9.
Protein context
Aldo-keto reductase family 1 member B1
Aldo-keto reductase family 1 member B1 Sequence length is 316 aa.
Review this target as Aldo-keto reductase family 1 member B1, mapped to UniProt P15121. Sequence length is 316 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P15121
Protein
Disease context
diabetes mellitus
Aldo-keto reductase family 1 member B1 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TOLRESTAT.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include TOLRESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 1035 compounds, and 224 assays for this target. The dominant activity type is IC50. CHEMBL2260162 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL2260162 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 9.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Aldo-keto reductase family 1 member B1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P15121, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why diabetes mellitus is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1035
Total Compounds
224
Total Assays
8
Approved Drugs
IC50: 1174.0, KI: 36.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2260162
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL2260155
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL1645381
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL2260152
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL1645384
|
9.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
EPALRESTAT
CHEMBL56337
|
1992 |
|
|
TOLRESTAT
CHEMBL436
|
1989 |
|
|
SULINDAC
CHEMBL15770
|
1978 |
Source Header